Blood Adv

Heightened lymphoma risk observed in BRCA1/2 carriers with textured implants

June 24, 2025

BRCA1/2 mutations are a significant risk factor for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in women with breast cancer and textured implants. These findings underscore the importance of genetic risk assessment in surgical planning and counseling for breast reconstruction, particularly in BRCA1/2 carriers considering textured implants.

Study details: A large cohort study evaluated 520 women with breast cancer who underwent mastectomy and reconstruction with textured implants, all of whom were tested for BRCA1/2 mutations. The prevalence of BRCA1/2 mutations was compared between those who developed BIA-ALCL and those who didn't. Hazard ratios (HRs) were calculated using Cox regression, and a case-control analysis was performed with 13 BIA-ALCL cases matched to 39 controls.

Results: Women with BRCA1/2 mutations had a 16-fold increased age-adjusted risk of developing BIA-ALCL compared with non-carriers (HR, 16; 95% confidence interval, 3.6–76.1, p < 0.0003). Neither bilateral implants, chemotherapy, nor radiation therapy were associated with increased BIA-ALCL risk. The case-control analysis further supported a strong association between BRCA1/2 status and BIA-ALCL (p = 0.0002).

Source:

Ghione P, et al. (2025, June 12). Blood Adv. BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants. https://pubmed.ncbi.nlm.nih.gov/40512039/